Sourced from GMP · ISO · Halal · Kosher certified facilities · FSSAI & APEDA registered exporter 📞 +91 8767675175 ✉ info@svbotanica.com
Home›Products›Nutraceuticals›Pterostilbene
Nutraceuticals
Request a Quote Request Free Sample WhatsApp Enquiry
Quick Specs
FormTrans-Pterostilbene
Purity≥99% (HPLC)
Bioavailability~80% oral
Shelf life24 months
MOQ1 kg (sample); 5 kg (commercial)
Nutraceuticals

Pterostilbene

Trans-Pterostilbene ≥99% Purity ~80% Bioavailability SIRT1 Activator
The methylated resveratrol analogue that solves the bioavailability problem — 80× better oral absorption, superior blood-brain barrier penetration, and SIRT1 activation at a fraction of the dose.
Pterostilbene (trans-3,5-dimethoxy-4'-hydroxystilbene) is a naturally occurring stilbenoid structurally analogous to resveratrol, differing by the substitution of two hydroxyl groups with methoxy groups on the A-ring. This seemingly small chemical modification has dramatic pharmacokinetic consequences: while resveratrol has ~1% oral bioavailability due to rapid phase-II conjugation, pterostilbene achieves ~80% oral bioavailability because its methoxy groups block the primary conjugation sites, allowing far greater systemic absorption. Found naturally in blueberries, grapes, and the heartwood of Pterocarpus marsupium (Indian kino tree), commercial supply is primarily via chemical synthesis or semi-synthesis from resveratrol, yielding >99% purity material. CAS 537-42-8.

Pterostilbene activates SIRT1 (sirtuin-1) similarly to resveratrol but at lower effective doses due to its superior bioavailability. It additionally acts as a PPARα agonist (relevant to lipid metabolism and fatty acid oxidation), crosses the blood-brain barrier more efficiently than resveratrol, and demonstrates COMT inhibition that supports dopaminergic neurotransmission. SV Botanica supplies ≥99% pterostilbene from certified manufacturers, GMP/ISO certified, batch-tested by HPLC. The longevity supplement category is the primary growth driver; pterostilbene is increasingly used alongside NMN (nicotinamide mononucleotide) and quercetin in premium anti-aging stacks.
Available specifications
    Quality Assurance

    ≥99% Trans-Isomer Confirmed. HPLC-Verified.

    Every Pterostilbene batch is tested by HPLC with specific trans-pterostilbene quantification and geometric isomer confirmation — not total stilbene content. Light-protected, nitrogen-packaged to prevent isomerisation during transit.

    01

    Trans-isomer HPLC verification

    COA explicitly confirms trans-pterostilbene content; cis-pterostilbene (inactive form) is identified and reported separately — not bundled into a "total stilbene" figure that obscures the biologically active fraction.

    02

    Nitrogen-flushed packaging

    Light and oxidation convert trans to cis isomer. All pterostilbene is shipped in opaque, nitrogen-flushed aluminium foil packaging to preserve geometric isomer integrity throughout transit and storage.

    03

    Heavy metals & purity panel

    Lead, mercury, arsenic, cadmium, residual solvents (ICH Q3C), and microbial testing per USP standards. Full panel reported on COA with every batch — not just assay and appearance.

    04

    Export documentation

    COA, MSDS, Certificate of Origin, and Phytosanitary Certificate with every shipment. GMP and ISO facility certification documents available digitally before shipment.

    Formulation Intelligence

    Pterostilbene vs Resveratrol: The Bioavailability Advantage Explained

    The supplement industry's obsession with resveratrol is well-documented — but formulators working in longevity and cognitive enhancement increasingly reach for pterostilbene because its pharmacokinetics solve resveratrol's fundamental limitation. Understanding the structural chemistry behind this difference allows buyers to make informed specifications and communicate the science convincingly on product labels.

    Superior Bioavailability

    Pterostilbene

    CAS: 537-42-8

    ~80% oral bioavailability due to methoxy group protection of conjugation sites. Once-daily dosing supported by 105-minute half-life. Effective at 50–150mg. Better blood-brain barrier penetration due to higher lipophilicity (logP 3.97). PPARα agonist and COMT inhibitor — activities not shared by resveratrol.

    The preferred choice when systemic delivery and CNS effects are the formulation goal.
    Lower Bioavailability

    Resveratrol

    CAS: 501-36-0

    ~1% oral bioavailability (rapid sulphation at hydroxyl groups at the 3- and 5-positions of the A-ring). Requires 500–1,000mg doses for comparable systemic effects. Strong clinical literature and consumer brand recognition. Lower cost per gram than pterostilbene.

    Best for label recognition and when combined with piperine for bioavailability enhancement.
    PPARα Agonist

    Lipid & Metabolic Effects

    Unique to pterostilbene — not seen with resveratrol

    Pterostilbene's methoxy groups increase lipophilicity and enable PPARα receptor binding. PPARα activation promotes fatty acid oxidation, reduces triglycerides, and increases HDL. Clinical study (Bharat et al., 2012): 100mg pterostilbene twice daily reduced LDL and total cholesterol vs placebo. Positioning: cardiovascular support supplements.

    Unique to pterostilbene — not seen with resveratrol.
    Cognitive Stack

    Blood-Brain Barrier Penetration

    logP 3.97 vs 2.86 for resveratrol

    Higher lipophilicity means pterostilbene crosses the blood-brain barrier more effectively than resveratrol. Animal studies show improved spatial memory, reduced hippocampal oxidative stress, and protection against amyloid pathology. Human cognitive studies in progress. Positioning: nootropic and healthy aging cognitive formulations.

    50–100mg doses shown effective in preclinical models.
    Buyer FAQ

    Frequently Asked Questions

    Pterostilbene and resveratrol are both stilbenoid polyphenols with nearly identical structures — the critical difference is that pterostilbene has two methoxy groups (-OCH₃) at the 3- and 5-positions of the A-ring, where resveratrol has hydroxyl groups (-OH). This structural change has dramatic functional consequences: hydroxyl groups are the primary sites of phase-II conjugation (sulphation and glucuronidation) in the gut and liver — the metabolic process that renders resveratrol biologically unavailable at ~1% oral bioavailability. Pterostilbene's methoxy groups block these conjugation sites, allowing approximately 80% of ingested pterostilbene to reach systemic circulation intact. Both compounds activate SIRT1, inhibit NF-κB, and have antioxidant properties — but pterostilbene achieves these effects at significantly lower doses due to its bioavailability advantage.
    Human clinical studies on pterostilbene have used doses ranging from 50mg to 250mg per day, significantly lower than the 500–1,000mg typically used for resveratrol. For SIRT1 activation and cardiovascular effects, studies show activity at 50–100mg/day. For cognitive and blood pressure effects, studies use 50–100mg twice daily. For longevity formulations combining pterostilbene with NMN or quercetin, 100–150mg pterostilbene per serving is typical. The compound is safe in human studies at up to 250mg/day, with no significant adverse events reported. Due to its longer half-life (~105 minutes vs resveratrol's ~14 minutes after conjugation), once-daily dosing is pharmacokinetically appropriate.
    Yes — pterostilbene is commonly included in multi-ingredient longevity stacks alongside NMN (nicotinamide mononucleotide), resveratrol, quercetin, and CoQ10. The rationale for combining pterostilbene with NMN is that both support the SIRT1/NAD⁺ axis through different mechanisms: NMN replenishes NAD⁺ (the substrate SIRT1 requires), while pterostilbene and resveratrol directly activate SIRT1. Adding quercetin extends the stack to include senolytic activity (clearing senescent cells). These combinations are mechanistically complementary and have not shown safety issues in human use, though clinical trial data on the specific combination is limited.
    For most supplement applications where systemic delivery is the goal, pterostilbene offers significant pharmacokinetic advantages over resveratrol: approximately 80% oral bioavailability vs ~1% for resveratrol, a longer plasma half-life, and better blood-brain barrier penetration. This means pterostilbene delivers measurable systemic effects at 100–150mg doses where resveratrol would require 500–1,000mg for comparable effects. Pterostilbene also has COMT-inhibitory and PPARα-agonist activities not shared by resveratrol. However, resveratrol has a much larger clinical literature base, stronger brand recognition with consumers, and is less expensive per gram. Premium longevity formulations increasingly include both — pterostilbene for bioavailable systemic delivery, resveratrol for label recognition.
    Every pterostilbene shipment includes: Certificate of Analysis (COA) confirming ≥99% pterostilbene by HPLC with specific trans-isomer identification (not total stilbenes), heavy metals panel (lead, mercury, arsenic, cadmium), moisture, and microbial testing; Material Safety Data Sheet (MSDS/SDS); Certificate of Origin; and GMP/ISO facility certification documents. Trans-isomer confirmation is critical — as with resveratrol, pterostilbene exists in active (trans) and inactive (cis) geometric forms, and COAs should explicitly confirm the trans-configuration.
    You May Also Need